Harmony Biosciences Holdings, Inc. $HRMY Shares Bought by American Century Companies Inc.

American Century Companies Inc. grew its holdings in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) by 16.5% in the second quarter, according to its most recent disclosure with the SEC. The fund owned 1,501,420 shares of the company’s stock after buying an additional 212,633 shares during the period. American Century Companies Inc. owned 2.61% of Harmony Biosciences worth $47,445,000 at the end of the most recent reporting period.

Other institutional investors have also recently added to or reduced their stakes in the company. Rhumbline Advisers lifted its position in Harmony Biosciences by 9.3% during the 2nd quarter. Rhumbline Advisers now owns 119,201 shares of the company’s stock worth $3,767,000 after acquiring an additional 10,128 shares during the period. Franklin Resources Inc. raised its stake in shares of Harmony Biosciences by 5.7% during the second quarter. Franklin Resources Inc. now owns 32,385 shares of the company’s stock worth $1,023,000 after purchasing an additional 1,745 shares during the last quarter. Legal & General Group Plc lifted its holdings in shares of Harmony Biosciences by 4.2% during the second quarter. Legal & General Group Plc now owns 114,932 shares of the company’s stock worth $3,632,000 after purchasing an additional 4,643 shares during the period. Hillsdale Investment Management Inc. grew its position in Harmony Biosciences by 71.9% in the 2nd quarter. Hillsdale Investment Management Inc. now owns 120,700 shares of the company’s stock valued at $3,814,000 after buying an additional 50,500 shares during the last quarter. Finally, EMC Capital Management acquired a new position in Harmony Biosciences in the 2nd quarter valued at $195,000. Institutional investors and hedge funds own 86.23% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have recently commented on HRMY. Oppenheimer restated an “outperform” rating and issued a $62.00 target price on shares of Harmony Biosciences in a research note on Monday. Wall Street Zen downgraded shares of Harmony Biosciences from a “buy” rating to a “hold” rating in a research report on Saturday, November 8th. UBS Group lowered their price objective on Harmony Biosciences from $50.00 to $43.00 and set a “buy” rating on the stock in a report on Wednesday, October 15th. HC Wainwright reiterated a “buy” rating and set a $55.00 target price on shares of Harmony Biosciences in a research report on Monday, November 24th. Finally, Deutsche Bank Aktiengesellschaft reduced their price target on Harmony Biosciences from $54.00 to $36.00 and set a “buy” rating for the company in a report on Thursday, September 25th. One equities research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and two have issued a Hold rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $44.75.

Harmony Biosciences Price Performance

Harmony Biosciences stock opened at $35.26 on Friday. Harmony Biosciences Holdings, Inc. has a 52 week low of $25.52 and a 52 week high of $40.93. The company has a quick ratio of 3.72, a current ratio of 3.75 and a debt-to-equity ratio of 0.18. The firm’s 50-day simple moving average is $29.97 and its 200 day simple moving average is $33.02. The firm has a market capitalization of $2.03 billion, a PE ratio of 11.09, a P/E/G ratio of 0.46 and a beta of 0.85.

Harmony Biosciences (NASDAQ:HRMY) last posted its earnings results on Tuesday, November 4th. The company reported $0.87 earnings per share for the quarter, missing the consensus estimate of $0.92 by ($0.05). Harmony Biosciences had a net margin of 22.50% and a return on equity of 24.88%. The business had revenue of $239.46 million for the quarter, compared to analysts’ expectations of $222.68 million. On average, equities research analysts predict that Harmony Biosciences Holdings, Inc. will post 2.43 EPS for the current fiscal year.

Harmony Biosciences Profile

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.